2013 News/Liver Cancer
2016 - Fibrosis/Cirrhosis/Liver Cancer/Transplants
Dec 17 2013
Stem Cell Clinical Trial for Hepatocellular Carcinoma
California Stem Cell, Inc. (CSC) announced today the successful completion of a Phase I clinical trial investigating the safety of a cancer stem cell-based therapy in patients with Stage IV hepatocellular carcinoma, a common form of advanced liver cancer. The trial, conducted in Shanghai, China in accordance with international standards, marks the second cancer type the Company has explored with its platform approach, the first being a Phase III treatment for melanoma in the United States.
November 3 2013
Slides/Abstracts @ NATAP
AASLD: THE RISK FOR HCC AMONG PATIENTS WITH CHRONIC HCV INFECTION AND ADVANCED HEPATIC FIBROSIS FOLLOWING SVR
Liver Meeting speaker: HCC exceptions contributing to MELD inflation, transplant inequity
“Regulatory authorities and the transplant community should decide whether transplant should be preferential to HCC [hepatocellular carcinoma], or whether it should treat all diseases equally,” he said. “The current system is self-fulfilling ... HCC exceptions have better wait-list survival and better short-term outcome.”...
AASLD-Hepatitis B and C are responsible for 71 percent of liver cancer deaths/58 percent of cirrhosis deaths
According to the study, chronic liver disease is a leading cause of human mortality. Hepatitis B and C are responsible for 71 percent of liver cancer deaths and 58 percent of cirrhosis deaths, whereas alcohol is responsible for 25 percent of all deaths caused by liver cancer and cirrhosis. The toll taken by hepatitis B and C differs by region with hepatitis C causing a greater number of deaths in the US and Western Europe, and hepatitis B causing more deaths in China and India.
In addition to recommending a greater priority to be given to viral hepatitis globally, the regional differences in the predominant cause of chronic liver disease -- hepatitis B, hepatitis C, and alcohol abuse -- prompted the study authors to recommend prevention responses to be specific to regional needs....
October 22 2013
Coffee Consumption Reduces Risk of Liver Cancer
Bethesda, MD (Oct. 22, 2013)
— Coffee consumption reduces risk of hepatocellular carcinoma (HCC), the most common type of liver cancer, by about 40 percent, according to an up-to-date meta-analysis published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.
NUS scientists identify molecular switch that suppresses development of liver cancer
Findings by researchers contribute towards the development and application of therapeutics for liver cancer
October 18 2013
Researchers identify liver cancer progenitor cells before tumors become visible
For the first time, researchers at the University of California, San Diego School of Medicine have isolated and characterized the progenitor cells that eventually give rise to malignant hepatocellular carcinoma (HCC) tumors – the most common form of liver cancer. The researchers found ways to identify and isolate the HCC progenitor cells (HcPC) long before actual tumors were apparent.
Sept 28 2013
Cancer biggest killer of Hispanic Texans
Combining Chinese and Western medicine could lead to new cancer treatments
Combining traditional forms of Chinese and Western medicine could offer new hope for developing new treatments for liver, lung, colorectal cancers and osteosarcoma of the bones.
Experts from Cardiff University's School of Medicine have joined forces with Peking University in China to test the health benefits of a traditional Chinese medicine.
The team also set-out to examine how by combining it with more traditional methods like Chemotherapy could improve patient outcomes and potentially lead to the development of new cancer treatments and therapies.
"Traditional Chinese medicine where compounds are extracted from natural products or herbs has been practised for centuries in China, Korea, Japan and other countries in Asia," according to Professor Wen Jiang from Cardiff University's School of Medicine, who is the director of the Cardiff University-Peking University Joint Cancer Institute at Cardiff and led the research as part of a collaboration between Cardiff University and Peking University.
"Although a few successes, most of the traditional remedies are short of scientific explanation which has inevitably led to scepticism – especially amongst traditionalists in the West.
"As a result, we set out to test the success of a Chinese medicine and then consider how combining it alongside traditional methods like Chemotherapy could result in positive outcome for patients," he adds.
Yangzheng Xiaoji is a traditional Chinese formula consisting of 14 herbs. The formula has been shown to be beneficial to cancer patients – however, until now how it works has remained unknown.
Since 2012 the Team have investigated how the formula works, discovering that it works by blocking a pathway which stops the spread of cancer cells in the body.
"The formula has been shown to be beneficial to patients with certain solid tumours, when used alone and in conventional therapies, such as Chemotherapy.
"It suggests that combining the formula with conventional as well as new therapies could hold the key to developing new treatments for cancer patients.
"We are already looking to clinical trials in treatment of lung and other cancer types."
Funded by Cancer Research Wales and the Albert Hung Foundation – the results will be presented at the European Cancer Congress 2013 which takes place in Amsterdam between the 27th September and 1st October.
New score predicts who will benefit from TACE retreatments
A new score accurately predicts which patients will benefit from repeated transarterial chemoembolization
(TACE) for hepatocellular carcinoma (HCC), researchers from Austria report.
Progression-free HCC survival with sorafenib linked to low AFP, more adverse events
Sept 12 2013
New grading system for radiofrequency ablation for hepatocellular carcinoma
A study in the latest issue of the Journal of Gastroenterology examines the relationship between a new grading system for the ablative margin and clinical outcome in hepatocellular carcinoma.
Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib in Patients With Advanced Hepatocellular Carcinoma
"Patients with advanced HCC who have progressed on sorafenib have few therapeutic options, and new approaches to managing their disease are much needed," said Ghassan K. Abou-Alfa, M.D., Associate Attending at Memorial
Sloan-Kettering Cancer Center, New York and the lead investigator on CELESTIAL.
"Phase 2 data investigating cabozantinib in this patient population are worthy of more study, and cabozantinib's target profile, which includes inhibition of both MET and VEGFR, is highly relevant in HCC."
Hepatitis B Vaccination Cuts Deaths From Liver Disease, Cancer: Study
Taiwanese researchers report a 90 percent reduction in deaths from complications of hepatitis B since the country began its infant vaccination program in 1984
Peru: Liver Cancer Like No Other
Liver cancer is the sixth most common cancer worldwide and the third most deadly.
Liver cancer due to chronic inflammation: tumour growth follows programmed cell death (apoptosis)
The death of numerous liver cells in the context of chronic inflammation due to apoptosis, a form of programmed cell death, can promote the formation of tumour cells in the liver
HCC treatment underutilized in the US
The number of patients in the US with hepatocellular carcinoma who undergo both any or specifically curative treatment is low, including those diagnosed at an early stage, according to recent results.
Risk factors for liver cancer in the USA - HCV, HBV, excessive alcohol, diabetes/obesity and rare genetic disorders
Aug 16 2013
Histopathology of hepatitis C liver disease for determining hepatocellular carcinoma risk factors
We evaluated the histopathological findings of hepatitis C liver disease to determine risk factors for the development of hepatocellular carcinoma (HCC), in 232 patients who underwent liver biopsy, with sustained virological response after interferon therapy.
Consequently, atypical hepatocytes among irregular regeneration of hepatocytes may be an important risk factor for HCC development, along with progression of liver fibrosis.
Impact of Coffee on Liver Diseases: A Systematic Review
HCC-4 risk score’ IDs hepatitis C patients likely to develop HCC
A risk score derived from four simple test results readily obtained during routine care may help identify
the patients with chronic hepatitis C who are most at risk for developing hepatocellular carcinoma, according
to a retrospective study published online July 12 in the European Journal of Internal Medicine.
TheraSphere® Recommended by the National Institute for Health and Care Excellence (NICE) for the
Treatment of Primary and Secondary Liver Cancer
National Institute for Health and Care Excellence (NICE) has issued guidance recommending the use of
Selective Internal Radiation Therapy (SIRT)(1), which includes TheraSphere®, for patients with
liver cancer across the NHS
The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers
July 18 2013
Watch; New surgical knife can instantly detect cancer - iKnife "Intelligent knife"
In the new study, the researchers first used the iKnife to analyse tissue samples collected
from 302 surgery patients, recording the characteristics of thousands of cancerous and
non-cancerous tissues, including brain, lung, breast, stomach, colon and liver tumours
to create a reference library. The iKnife works by matching its readings during surgery to
the reference library to determine what type of tissue is being cut, giving a result in less than three
The technology was then transferred to the operating theatre to perform real-time analysis
during surgery. In all 91 tests, the tissue type identified by the iKnife matched the post-operative
diagnosis based on traditional methods.
July 2 2013
Preliminary results suggest safety, efficacy of tremelimumab as HCC, HCV therapy
Sangro B. J Hepatol. 2013;59:81-88.
Patients with hepatocellular carcinoma and chronic hepatitis C may experience antiviral and antitumoral benefits
from treatment with tremelimumab, according to results of a recent pilot study.
In the phase 2, noncontrolled, multicenter, open-label trial, researchers administered 15 mg/kg tremelimumab
intravenously daily to 21 adult patients with chronic HCV genotype 1b and hepatocellular carcinoma (HCC) for
90 days for a maximum of four cycles or until severe toxicity or tumor progression occurred. Toxicity was evaluable
in 20 participants and tumor response was measurable in 17 cases.
Gut microbes spur liver cancer in obese mice
The gut bacteria of obese mice unleash high levels of an acid that promotes liver cancer, reveals one of the first studies
to uncover a mechanism for the link between obesity and cancer. The research is published today in Nature
Sex, race determine major risk factors for HCC in older patients
Does Successful Hepatitis C Treatment Eliminate Liver Cancer Risk?
Hepatocellular carcinoma: Clinical study of long-term survival and choice of treatment modalities
This study was approved by the internal review board and ethics committee of the hospital. Informed
consent was not required because of the retrospective and anonymous nature of the study, although
these data were derived from prospective statistics for in patients.
June 6 2013
Common solvent linked to liver cancer risk
June 1 2013
Watch - Liver cancer is one of the fastest rising cancers in Canada
Hepatitis C: Am I At Risk For Liver Cancer?
Consumption of Coffee Associated With Reduced Risk of Liver Cancer - A Meta-Analysis
What does the latest scientific evidence say about the connection between coffee consumption and liver cancer? Does it offer protective benefits?
May 23, 2013
HIV Is No Barrier To Successful Liver Transplant For Cancer Treatment
Zinc supplements may be beneficial for those with hep C
A recent study published in the Journal of Clinical Biochemistry and Nutrition has found that people with hepatitis C may reduce their risk of liver cancer if they take a zinc supplement.
Arterial studies add little to CT for finding liver cancer
Advanced Liver Cancer - Bayer Initiates Phase III Trial of Regorafenib
Delcath Shares Halted as FDA Discusses New Drug Application for Liver-Cancer Treatment
EASL 2013- Watch: HCC, NAFLD and NASH
EASL - Novel screening tests for liver cancer
A risk for hepatocellular carcinoma still persists long-term after sustained virological response in patients with hepatitis C associated liver cirrhosis
Clinical Infectious Diseases, 04/26/2013 Clinical Article
Aleman S et al. – The long–term effect of sustained virological response (SVR) to antiviral therapy on the risk to develop hepatocellular cancer (HCC), liver complications, liver–related deaths and overall death in hepatitis C (HCV)
infected patients with liver cirrhosis is not fully known.
The risk for HCC, liver decompensation, and death in patients with liver cirrhosis related to HCV was markedly reduced after SVR, but a long–term risk to develop HCC remains for up to 8 years. Cirrhotic patients with HCV who achieve SVR should therefore maintain long–term surveillance for HCC. Future studies aimed to better identify those with remaining long–term risk for HCC are needed.
- These risks were evaluated during long–term follow–up in in 351 patients
with HCV related cirrhosis.
- 110 with SVR, 193 with non–SVR and 48 untreated patients were included in a
multi–center cohort which was initiated 2001 and prospectively followed–up for a
mean 5.3 ±SD 2.8 years.
- Complementary follow–up data from national registries were used to minimize
the loss of patients during follow–up.
- Six patients with SVR developed HCC at 0.04, 0.64, 2.4, 7.4, 7.4 and 7.6
years after achieving SVR.
- The incidence of HCC, any liver complication, liver–related and overall
death per 100 person–years was significantly lower in SVR time with 1.0, 0.9,
0.7, 1.9, compared to 2.3, 3.2, 3.0, 4.1 and 4.0, 4.9, 4.5, 5.1 in non–SVR and
untreated time, respectively.
- The long–term consequences did not decline significantly after more than
3–year versus during the first 3–year of
New In Multimedia
Professor Colombo talks candidly about our understanding of hepatocellular carcinoma.
When Standard Liver Cancer Treatment Doesn't Work Or Isn't Possible,
New Ablation Technique Holds Promise
Liver Cancers Armed With Many Strategies For Evading Immune Response
Mount Sinai Invents Gene Signature to Identify Individuals with Cirrhosis at High-Risk for Liver Cancer
Role for Radiation in Locally Advanced Liver Cancer
Alpha-fetoprotein useful marker in HCC
Mar 5 2013
Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma: A Meta-analysis of Observational Studies
Liver Cancer in People with Hepatitis C: Part 2–HCC Treatment and Management
Over years or decades, chronic hepatitis B or C can lead to advanced liver disease including cirrhosis and hepatocellular carcinoma (HCC), a type of primary liver cancer. While HCC remains among the most difficult-to-treat cancers, there have been some encouraging developments in recent years.
This article discusses treatment options for HCC, focusing on targeted molecular therapy.
Part 1, in the February 2013 HCV Advocate, looked at HCC risk factors, screening, and hepatitis B and C treatment for preventing liver cancer....Continue Reading...
Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis
Feb 14 2013
Key Molecule Suppresses Growth of Cancerous Liver Tumors, Mayo Study Finds
Poor HCC surveillance common; may contribute to late-stage tumors
Hepatic function testing can assist in treatment planning for liver cancer patients
New Patient Focused Website - Liver Cancer Connect
Liver Cancer-Phase III HEAT trial of Thermodox Fails to Meet Goals
Clinical Liver Disease, an online learning resource from AASLD, is pleased to announce an issue devoted to
the important topic of Current Issues in Hepatocellular Carcinoma.
Click here to view this issue of CLD
HCC incidence increased in HIV/hepatitis coinfection
Scientists Discover Process That Turns Normal Liver Cells to Cancer Cells
Cancer risk much greater among men
No Added Benefit for Chemo Beads in Liver Cancer
Statins May Lower Death Risk in Liver Ca (CME/CE)
Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance
This week in an analysis of HALT-C data, investigating the surveillance of liver cancer in academic centers published by
the American Journal of Gastroenterology, reported only 20% of hepatocellular carcinoma (HCC), was found at a very early stage.
*Free registration required
Watch - Statins Are Associated With a Reduced Risk of Hepatocellular Cancer
Model assesses HCC risk according to age, platelet counts
Early hepatocellular carcinoma – Is there such a thing as too early?
Screening combo finds HCC in cirrhosis patients
UAMS Has New Weapon to Fight Liver Cancer
Paired CT Scans Catch Chemo-Killing of Liver Tumors in Real Time
Hepatitis C Cirrhosis Patients with Sustained Treatment Response Have Lower Risk of Death
Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas in the United States: Similarities and Differences
Watch - Bruno Daniele, MD: Liver Cancer Research Update